Friday, October 2, 2026
ExploreSearch
Finance Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 2, 2026

Mawson Infrastructure Group Inc. Adopts Limited Duration Stockholder Rights Agreement

View original at globenewswire.com
Mawson Infrastructure Group Inc. Adopts Limited Duration Stockholder Rights Agreement MIDLAND, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- MAWSON INFRASTRUCTURE GROUP Inc…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Endeavor purported combined ownership of shares amounting to 48.0% of shares outstanding as of January 28, 2026

    80% confidence

  • The Rights Agreement does not preclude the Board from considering proposals, engaging in discussions or pursuing transactions that it believes are in the best interests of Mawson and its stockholders

    80% confidence

  • Endeavor purported combined ownership of shares amounting to 31.6% of shares outstanding as of January 6, 2026

    80% confidence

  • Based on Mawson's records, Endeavor's purported 48.0% ownership actually amounted to 29.7% of shares outstanding

    80% confidence

  • Based on Mawson's records, Endeavor's purported 31.6% ownership actually amounted to 19.5% of shares outstanding

    80% confidence

  • The Rights Agreement is intended to enable Mawson's stockholders to realize the long-term value of their investment and protect its stockholders from actions of third parties that the Board determines are not in the best interests of Mawson and its stockholders

    80% confidence

  • Endeavor did not have any present plan or proposal that would result in an extraordinary corporate transaction or a change in the Board or management of the Company

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI-Driven Drug Development Meets Biotech Deal-Making and Regulatory Catalysts
AI-designed therapeutics (Insilico's rentosertib showing biological-age reductions) are moving into the clinical mainstream. Large-cap biotech is simultaneously reallocating capital through M&A (Lilly–Merida, $2.9B) and government funding (BARDA–Basilea), while trial failures (ziltivekimab, a 9.4% Novo Nordisk share drop) and upcoming FDA catalysts (the ivonescimab PDUFA on 2026-11-14) drive volatility. The wider AI regulatory and legal climate (Tesla Cybercab probe, xAI's Minnesota loss, OpenAI suits) is tightening, though QAIAx's micro-cap trial claims are speculative and weakly connected.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,327 source documents archived
Query this data → isubstrate.com